Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy
Launched by UCB PHARMA · Mar 25, 2008
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female older than 16 years;
- • Epilepsy with partial onset seizures, with or without secondary generalization;
- • At least one concomitant marketed anti-epileptic drug
- Exclusion Criteria:
- • Safety reasons
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
UCB Clinical Trial Call Center
Study Director
+1 877 822 9493 (UCB)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials